Successful Technology Licensing (STL)

Train the Trainers ProgramRio de Janeiro, Brazil, March 28 to 31, 2006

Theme 10Simulation of a Licensing NegotiationIntroduction to the Game (Diagram)

BIO MED

BUSINESS OBJECTIVES

Leverage

NEGOTIATION STRATEGY

“Bottom line” - limited exclusivity

“First line” - assignmentof IP rights or WorldwideExclusivity on Nano chip

University Needs Funds forResearch

Cluster I

Cluster II

Cluster III

Technology Status(Completed or Not)

Nanolin Not Clinically Tested

Nano-Chip not finalized

Scope for Nanolin and Nano-Chip License

May be different

Right to Modify and Improve

IP Ownershipor Unlimited Exclusivity

Large Potential Marketfor Nanolin (20 billionUS Dollars)

Cap Royalties

Cluster IV

Want to Control future Developmentof the Technologies

Clarify Subject Matter(Nanolin and Nano-Chip)

IP Ownership?

Clinical Trial Costs

Up Front Fee or Lump-Sum Payment for Research

Limited Responsibility for Risk

Dr. Cruz as Employee of Bio Med

UNIVERSITY DO LITORAL

BUSINESS OBJECTIVES

Leveragefor University

NEGOTIATION STRATEGY

Alternative Financing From Dr. Lattes

Cluster I

Cluster II

Cluster III

Need to complete clinical testing

Nee to complete the technologyfor Nanolin and Nano-Chip

IP Ownership(University

Policy)

Nano-chip Universal Testing Tool

IP Ownership

To keep right to modify

In-exclusive for Nanochip

Ready to give exclusive license for

Nanoline

BioMed to payIndemnities

Minimum royalties

Large market, potentialnett Cash flow in 5 yrs- 875.5 million U.S.

BioMed to pay cost of clinical testing

Up-front feefor research

Cluster IV

Want right on new versions on Nano-Chip

To keep new versions of Nano-Chip

Limit Dr. Crus’s BioMed cooperation on consultancy level

Need funds for research

Distribution of Nanolin for public health

Keep control over use of Nanolin Chip

Nanolin Drug with potential huge Market

Dr. Octavio CruzMr. Lui Antonio SimonMr. Raul Barbosa